Get more for you money! Shop Berman Instruments
Dentist preferred. Value driven. Start saving!
  1. Home
  2. /
  3. Business

DENTSPLY Sirona: Byte a WAMGR Play, We Like Deal on First Pass

Published on: Apr 21, 2022
By: Jeff D. Johnson, O.D., CFA
Share Article

Republished. Original Source: Baird Equity Research

January 4, 2021

 

DENTSPLY Sirona (XRAY) announced today it has acquired Byte, a leading direct-to-consumer clear aligner company, for $1.04B (all-cash deal). With this deal, management expects its clear aligner business (Byte+SureSmile) to exceed a $300M run-rate by end of 2021, meaning this fast-growing segment of XRAY's business could account for nearly 10%of company-wide revenue by year end. While leverage ticks back up with this deal (net debt/2021 ebitda ~3.1x), we like the WAMGR play here and, on first pass, believe it makes sense for XRAY longer-term.

  • XRAY announced today it has acquired Byte, a leading direct-to-consumer clear aligner company, in an all-cash deal for $1.04 billion. While Byte's recent revenue wasn't provided, management expects Byte to generate run-rate sales of at least $200M in 2021.

  • Management expects immediate accretion - Management is using cash on the balance sheet to fund this deal and expects it to be $0.05 accretive to non-GAAP EPS this year. While we estimate this deal will increase XRAY's net debt to 2021 EBITDA to just over 3x, Byte will also bring with it an NPV tax benefit of ~$160M, which should provide cash flow help to XRAY over coming quarters.

  • Mutually beneficial WAMGR play. Management will host a call this morning at 7:30am to further discuss this transaction, but on first pass we like this deal for a few reasons:

    • First, with management estimating the combination of Byte and XRAY’s own SureSmile business could generate run-rate sales exceeding $300M by the end of 2021, we estimate this deal could add at least 100bp to XRAY’s long-term revenue growth rate (conservatively assuming 10-20% annual growth for these combined businesses over next few years).

    • We also see mutually beneficial opportunities with this deal, as Byte should benefit from XRAY's R&D capabilities (SureSmile tooth movement technology well regarded by docs) and commercial expertise, while XRAY likely benefits from Byte's direct-to-consumer capabilities that could help XRAY better connect patients with its network of dental partners.

    • We're also encouraged to hear that Byte management will continue to run the Byte business, which is what we'd want to hear when a start-up like this is acquired by a bigger company like XRAY.

 

DETAILS

Valuation

Our $58 price target on XRAY applies a 22x multiple to our 2022 EPS projection of $2.61. This 22x multiple we’re using to value XRAY is one point below the 23x median EPS multiple at which we estimate XRAYs broader medtech peer group currently trades and is in line with the 22x multiple we’re also using to value XRAY’s closest peer in NVST. Relative to medtech peers, we believe this one-point multiple discount is warranted by the slower demand recovery we expect for dental vs. other medtech areas and the greater secular challenges we see for dental in general vs. many medtech subsectors over coming years. Relative to NVST, we believe both companies currently warrant similar (equal, in our case) multiples as we believe both have similar low- to mid-single-digit top-line and upper-single- to low-double-digit intermediate-term EPS growth opportunities over the next several years.

 

INVESTMENT THESIS

While we remain concerned about the potential pace of recovery for the global dental market over the next 12-18 months and see reasons to be cautious on XRAY into 4Q-20 (a tough comp driven by strong Primescan demand in last year’s 4Q), we continue to recommend purchase of this stock at current levels for three main reasons.

  1. Primescan/Primemill demand expected to recover early next year. Before the onset of the global COVID-19 pandemic in March, our checks were suggesting Primescan demand was still strong early in the year and that interest from current CEREC owners for Primemill was trending better than we initially anticipated. As the dental market has started to recover in recent months, XRAY has since re-initiated a Primescan and Primemill trade-in program in the U.S. that we're hearing has so far generated reasonable levels of interest and could continue into next year, while management also recently seemed to confirm it is considering expanding these upgrade programs into Europe and Asia/Pac next year (our checks suggest XRAY's has a fairly sizable installed CEREC base in Germany, Japan, and Australia). After underestimating CEREC AC upgrade demand in the midst of the Great Recession back in 2009 and watching Sirona deliver five straight quarters of better-than-expected company-wide growth coming out of the recession, we don't want to underestimate a similar potential recovery for Primescan and Primemill coming out of the recent COVID-19 downturn.

  2. History also suggests near-term risk is greater for basic, rather than high tech, dental equipment. When again using the Great Recession as a proxy, we saw dental consumables revenue across the industry return to growth in 2010 after declining y/y in 2009, with consumables revenue for companies such as HSIC and PDCO higher in 2010 than in 2008. But it took these same companies four years before they were able to get their dental equipment revenue to return to 2008 absolute levels, as dentists remained hesitant to purchase equipment, especially basic equipment that doesn’t offer a practice real financial payback or efficiency gains. Demand for high tech equipment, however, rebounded faster (as evidenced by SIRO’s solid rebound to positive revenue growth by mid-2009), and with XRAY much more levered to high-tech rather than basic equipment and with new high-tech equipment products beyond Primescan and Primemill just recently launching (including the company's larger FOV Axeos 2D/3D imaging system and a new 3D printer under the trade name PrimePrint that we believe could launch over the next few quarters), we again see potential reasons to believe XRAY’s post-COVID dental equipment recovery could surprise investors over coming quarters.

  3. Secular shifts could provide revenue/margin tailwinds for three largest manufacturers. While we’re concerned about the potential pace of recovery in dental demand across the globe into 2021 given continued COVID-19 uncertainties and potential employment/discretionary spending overhangs, we also continue to hear in our checks that large DSOs are inching closer and closer to announcing direct supply agreements with manufacturers, potentially for contracts as soon as 2021. With COVID-19 issues also potentially driving even greater DSO consolidation over time (including potentially driving more private practices to consider selling to a DSO) and more DSOs potentially willing to move towards direct supply agreements once a couple of the larger organizations make such a move, we believe these types of direct moves would have positive revenue and margin implications for dental manufacturers, especially the three largest (XRAY, NVST, 3M) that we believe would be in the best position to directly support these DSOs over time. While revenue/margin contributions from such changes in 2021 would likely be fairly modest for a company such as XRAY (or NVST), we believe this shift in the dental purchasing paradigm would have positive valuation implications for dental manufacturers and potentially create additional valuation headwinds for dealers, thus our more positive bias at present on dental manufacturers over dealers.

  4. Bottom line is we believe that given the views above, and with management recently announcing an expansion of recent restructuring efforts that we estimate could drive an incremental $100M in cost savings on top of the $140M in cost savings prior efforts have generated over the past 18-24 months, we believe a path back toward 2019 margins in 2021 remains. In turn, we believe that could also translate to EPS for XRAY next year that at least rebounds back towards 2019 levels, suggesting shares of XRAY currently trade a bit under 23x our 2021 EPS projection of $2.30. This is in line to a slight discount to broader medtech peers that we estimate are currently trading at 23x current Street EPS assumptions for 2021, which in turn we believe leaves room for XRAY shares to move into the upper-$50s over the coming year.

RISKS & CAVEATS

Risks to achieving our price target objective include: (1.) highly competitive industry, (2.) longer-term potential changes in relationships with dental dealers, as 50% of company-wide revenue is tied to products sold through dental distributors, (3.) financial and integration risk associated with potential future M&A activity, (4.) general macroeconomic risk, especially in the near term as COVID-19 issues raise global macroeconomic questions, and (5.) risk that the coronavirus headwinds that are expected to impact XRAY significantly in 2020 may not resolve as quickly as we currently expect heading into 2021.

 

COMPANY DESCRIPTION

Dentsply and Sirona completed their merger in February 2016 and brought together the leading manufacturer in consumables (XRAY; ~13% share of ~$19B market) and equipment (Sirona; ~25%share of ~$5.5B market), with the combined company now participating in nearly every major consumables and equipment category in dentistry and typically enjoying the No. 1 or No. 2 worldwide market share position in the major product categories in which it competes.

 

Appendix - Important Disclosures and Analyst Certification

Approved on 04 January 2021 08:39EST/ Published on 04 January 2021 08:44 EST.

1 Robert W. Baird & Co. Incorporated makes a market in the securities of XRAY.

 

Appendix – Important Disclosures and Analyst Certification

Robert W. Baird & Co. Incorporated (“Baird”) and/or its affiliates expect to receive or intend to seek investment-banking related compensation from the company or companies mentioned in this report within the next three months. Baird may not be licensed to execute transactions in all foreign listed securities directly. Transactions in foreign listed securities may be prohibited for residents of the United States. Please contact a Baird representative for more information.

Investment Ratings: Outperform (O) - Expected to outperform on a total return, risk-adjusted basis the broader U.S. equity market over the next 12 months. Neutral (N) - Expected to perform in line with the broader U.S. equity market over the next 12 months. Underperform (U) - Expected to underperform on a total return, risk-adjusted basis the broader U.S. equity market over the next 12 months.

Risk Ratings: L - Lower Risk - Higher-quality companies for investors seeking capital appreciation or income with an emphasis on safety. Company characteristics may include: stable earnings, conservative balance sheets, and an established history of revenue and earnings. A - Average Risk - Growth situations for investors seeking capital appreciation with an emphasis on safety. Company characteristics may include: moderate volatility, modest balance-sheet leverage, and stable patterns of revenue and earnings. H - Higher Risk – Higher-growth situations appropriate for investors seeking capital appreciation with the acceptance of risk. Company characteristics may include: higher balance-sheet leverage, dynamic business environments, and higher levels of earnings and price volatility. S - Speculative Risk – High growth situations appropriate only for investors willing to accept a high degree of volatility and risk. Company characteristics may include: unpredictable earnings, small capitalization, aggressive growth strategies, rapidly changing market dynamics, high leverage, extreme price volatility and unknown competitive challenges.

Valuation, Ratings and Risks. The recommendation and price target contained within this report are based on a time horizon of 12 months but there is no guarantee the objective will be achieved within the specified time horizon. Price targets are determined by a subjective review of fundamental and/or quantitative factors of the issuer, its industry, and the security type. A variety of methods may be used to determine the value of a security including, but not limited to, discounted cash flow, earnings multiples, peer group comparisons, and sum of the parts. Overall market risk, interest rate risk, and general economic risks impact all securities. Specific information regarding the price target and recommendation is provided in the text of our most recent research report.

Distribution of Investment Ratings. As of December 31, 2020, Baird U.S. Equity Research covered 728 companies, with 64% rated Outperform/Buy, 35% rated Neutral/Hold and 1% rated Underperform/Sell. Within these rating categories, 14% of Outperform/Buy-rated and 4% of Neutral/Hold-rated companies have compensated Baird for investment banking services in the past 12 months and/or Baird managed or co-managed a public offering of securities for these companies in the past 12 months.

Analyst Compensation. Research analyst compensation is based on: (1) the correlation between the research analyst's recommendations and stock price performance; (2) ratings and direct feedback from our investing clients, our institutional and retail sales force (as applicable) and from independent rating services; (3) the research analyst's productivity, including the quality of such analyst's research and such analyst's contribution to the growth and development of our overall research effort; and (4) compliance with all of Baird’s internal policies and procedures. This compensation criteria and actual compensation is reviewed and approved on an annual basis by Baird's Research Oversight Committee. Research analyst compensation is derived from all revenue sources of the firm, including revenues from investment banking. Baird does not compensate research analysts based on specific investment banking transactions.

A complete listing of all companies covered by Baird U.S. Equity Research and applicable research disclosures can be accessed at http://www.rwbaird.com/research-insights/research/coverage/third-party-research-disclosures.aspx. You can also call 800-792-2473 or write: Robert W. Baird & Co., Equity Research, 777 E. Wisconsin Avenue, Milwaukee, WI 53202.

Analyst Certification

The senior research analyst(s) certifies that the views expressed in this research report and/or financial model accurately reflect such senior analyst's personal views about the subject securities or issuers and that no part of his or her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report.

Disclaimers

Baird prohibits analysts from owning stock in companies they cover.

This is not a complete analysis of every material fact regarding any company, industry or security. The opinions expressed here reflect our judgment at this date and are subject to change. The information has been obtained from sources we consider to be reliable, but we cannot guarantee the accuracy.

ADDITIONAL INFORMATION ON COMPANIES MENTIONED HEREIN IS AVAILABLE UPON REQUEST

The Dow Jones Industrial Average, S&P 500, S&P 400 and Russell 2000 are unmanaged common stock indices used to measure and report performance of various sectors of the stock market; direct investment in indices is not available. Baird is exempt from the requirement to hold an Australian financial services license. Baird is regulated by the United States Securities and Exchange Commission, FINRA, and various other self-regulatory organizations and those laws and regulations may differ from Australian laws. This report has been prepared in accordance with the laws and regulations governing United States broker-dealers and not Australian laws.

Other Disclosures

The information and rating included in this report represent the research analyst’s views based on a time horizon of 12 months, as described above, unless otherwise stated. In our standard company-specific research reports, the subject company may be designated as a “Fresh Pick”, representing that the research analyst believes the company to be a high-conviction investment idea based on a subjective review of one or more fundamental or quantitative factors until an expiration date specified by the analyst but not to exceed nine months. The Fresh Pick designation and specified expiration date will be displayed in standard company-specific research reports on the company until the occurrence of the expiration date or such time as the analyst removes the Fresh Pick designation from the company in a subsequent, standard company-specific research report. The research analyst(s) named in this report may, at times and at the request of clients or their Baird representatives, provide particular investment perspectives or trading strategies based primarily on the analyst’s understanding of the individual client’s objectives. These perspectives or trading strategies generally are responsive to client inquiries and based on criteria the research analyst considers relevant to the client. As such, these perspectives and strategies may differ from the research analyst’s views contained in this report.

Baird and/or its affiliates may provide to certain clients additional or research supplemental products or services, such as outlooks, commentaries and other detailed analyses, which focus on covered stocks, companies, industries or sectors. Not all clients who receive our standard company-specific research reports are eligible to receive these additional or supplemental products or services. Baird determines in its sole discretion the clients who will receive additional or supplemental products or services, in light of various factors including the size and scope of the client relationships. These additional or supplemental products or services may feature different analytical or research techniques and information than are contained in Baird’s standard research reports. Any ratings and recommendations contained in such additional or research supplemental products are consistent with the research analyst’s ratings and recommendations contained in more broadly disseminated standard research reports. Baird disseminates its research reports to all clients simultaneously by posting such reports to Baird’s password-protected client portal, https://bol.rwbaird.com/Login

(“BairdOnline”). All clients may access BairdOnline and at any time. All clients are advised to check BairdOnline for Baird’s most recent research reports. After research reports are posted to BairdOnline, such reports may be emailed to clients, based on, among other things, client interest, coverage, stock ownership and indicated email preferences, and electronically distributed to certain third-party research aggregators, who may make such reports available to entitled clients on password-protected, third-party websites. Not all research reports posted to BairdOnline will be emailed to clients or electronically distributed to such research aggregators. To request access to Baird Online, please visit https://bol.rwbaird.com/Login/RequestInstLogin

or contact your Baird representative.

Dividend Yield. As used in this report, the term “dividend yield” refers, on a percentage basis, to the historical distributions made by the issuer relative to its current market price. Such distributions are not guaranteed, may be modified at the issuer’s discretion, may exceed operating cash flow, subsidized by borrowed funds or include a return of investment principal.

United Kingdom (“UK”) disclosure requirements for the purpose of distributing this research into the UK and other countries for which Robert W. Baird Limited holds a MiFID passport.

The contents of this report may contain an "investment recommendation", as defined by the Market Abuse Regulation EU No 596/2014 ("MAR"). This report does not contain a “personal recommendation” or “investment advice”, as defined by the Market in Financial Instruments Directive 2014/65/EU (“MiFID”). Please therefore be aware of the important disclosures outlined below. Unless otherwise stated, this report was completed and first disseminated at the date and time provided on the timestamp of the report. If you would like further information on dissemination times, please contact us. The views contained in this report: (i) do not necessarily correspond to, and may differ from, the views of Robert W. Baird Limited or any other entity within the Baird Group, in particular Robert W. Baird & Co. Incorporated; and (ii) may differ from the views of another individual of Robert W. Baird Limited.

This material is distributed in the UK and the European Economic Area (“EEA”) by Robert W. Baird Limited, which has an office at Finsbury Circus House, 15 Finsbury Circus, London EC2M 7EB and is authorized and regulated by the Financial Conduct Authority (“FCA”) in the UK.

For the purposes of the FCA requirements, this investment research report is classified as investment research and is objective. This material is only directed at and is only made available to persons in the EEA who would satisfy the criteria of being "Professional" investors under MiFID and to persons in the UK falling within Articles 19, 38, 47, and 49 of the Financial Services and Markets Act of 2000 (Financial Promotion) Order 2005 (all such persons being referred to as “relevant persons”). Accordingly, this document is intended only for persons regarded as investment professionals (or equivalent) and is not to be distributed to or passed onto any other person (such as persons who would be classified as Retail clients under MiFID).

All substantially material sources of the information contained in this report are disclosed. All sources of information in this report are reliable, but where there is any doubt as to reliability of a particular source, this is clearly indicated. There is no intention to update this report in future. Where, for any reason, an update is made, this will be made clear in writing on the research report. Such instances will be occasional only.

Please note that this report may provide views which differ from previous recommendations made by the same individual in respect of the same financial instrument or issuer in the last 12 months. Information and details regarding previous recommendations in relation to the financial instruments or issuer referred to in this report are available at https://baird.bluematrix.com/sellside/MAR.action.

Robert W. Baird Limited or one of its affiliates may at any time have a long or short position in the company or companies mentioned in this report. Where Robert W. Baird Limited or one of its affiliates holds a long or short position exceeding 0.5% of the total issued share capital of the issuer, this will be disclosed separately by your Robert W. Baird Limited representative upon request.

Investment involves risk. The price of securities may fluctuate, and past performance is not indicative of future results. Any recommendation contained in the research report does not have regard to the specific investment objectives, financial situation and the particular needs of any individuals. You are advised to exercise caution in relation to the research report. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.

Robert W. Baird Limited and Robert W. Baird & Co. Incorporated have in place organisational and administrative arrangements for the prevention, avoidance, and disclosure of conflicts of interest with respect to research recommendations. Robert W. Baird Limited’s Conflicts of Interest Policy, available here, outlines the approach Robert W. Baird Limited takes in relation to conflicts of interest and includes detail as to its procedures in place to identify, manage and control conflicts of interest. Robert W. Baird Limited and or one of its affiliates may be party to an agreement with the issuer that is the subject of this report relating to the provision of services of investment firms. Robert W. Baird & Co. Incorporated’s policies and procedures are designed to identify and effectively manage conflicts of interest related to the preparation and content of research reports and to promote objective and reliable research that reflects the truly held opinions of research analysts. Robert W. Baird & Co. Incorporated’s research analysts certify on a quarterly basis that such research reports accurately reflect their personal views.

This material is strictly confidential to the recipient and not intended for persons in jurisdictions where the distribution or publication of this research report is not permitted under the applicable laws or regulations of such jurisdiction.

Robert W. Baird Limited is exempt from the requirement to hold an Australian financial services license and is regulated by the FCA under UK laws, which may differ from Australian laws. As such, this document has not been prepared in accordance with Australian laws.

Copyright 2021 Robert W. Baird & Co. Incorporated

This information is prepared for the use of Baird clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Baird. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this information (including any investment ratings, estimates or price targets) without first obtaining expressed permission from an authorized officer of Baird.

Dental Slang Podcast

Debunk common dental insurance myths with Dr. Travis Campbell. In this podcast, we discuss coding, when to file a claim (and when not to), as well as the right time to take an x-ray.

You May Also Like

2022-11-21

How to Get More for your Money in 2023

by Dr. Louis Berman

I bet when you’re shopping for a TV or laptop, you go to multiple websites to see who can give you the best price, right? Are you doing that when purchasing supplies?
2022-10-27

Video Discussion: Fight Rising Costs and Remain Profitable During Inflation

by Drs. Lou Berman & Travis Campbell

Rising supply costs, out of control inflation, increasing wage demands, decreasing insurance reimbursements and overall challenges when it comes to overhead control.
2022-06-14

Why Do We Deal with Insurance?

by Dr. Travis Campbell

According to an ADA study from 2015, the number one reason cited by far from patients (59%) on why they do not go to the dentist is cost.